| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |